Australia Seeks To Join Apotex In Suit Against Sanofi For Delaying Generic
This article was originally published in PharmAsia News
Executive Summary
The Australian government has filed to join an Apotex suit against Sanofi, claiming the France-based company delayed generics of its Plavix (clopidogrel) anticoagulant from the market, costing the treasury more than $130 million a year.
You may also be interested in...
Australian Court Dismisses Government’s AUD325m Claim For Generic Delay
Australia’s Full Court has dismissed the Commonwealth’s appeal against a 2020 judgment, which ruled it was not entitled to compensation from Sanofi as a result of the delayed entry of clopidogrel into the Australian market.
Australian Court Dismisses Government’s AUD325m Claim For Generic Delay
Australia’s Full Court has dismissed the Commonwealth’s appeal against a 2020 judgment, which ruled it was not entitled to compensation from Sanofi as a result of the delayed entry of clopidogrel into the Australian market.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.